

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.5(a)(4).

Dated: January 11, 2008 Electronic Signature: /Izumi Yokoyama, Ph.D./
(Izumi Yokoyama, Ph.D.)

Request for Expedited Procedure
Under 37 CFR § 1.16
Group Art Unit: 1625
Docket No.: A0345.0003
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Hamed Aissaoui et al.

Confirmation No.: 1663

Application No.: 10/501,054

Art Unit: 1625

Filed: September 15, 2004

Examiner: D. M. M. Seaman

For: NOVEL QUINOLINE DERIVATIVES

New York, NY
January 11, 2008

RESPONSE TO FINAL ACTION UNDER 37 C.F.R. 1.116

MS AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated December 20, 2007, finally rejecting claims 1-22, please reconsider the above-identified U.S. patent application in view of the following argument/remarks by Applicants:

Remarks/Arguments begin on page 2 of this paper.